Email Campaign to Increase Uptake of myGeisinger
Email Campaign to Encourage Patients to Complete Sign-up Process for Geisinger's Patient Portal
1 other identifier
observational
14,099
1 country
1
Brief Summary
The purpose of the current study is to test different email messages to determine the most effect way of promoting enrollment in Geisinger's patient portal, called myGeisinger.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 31, 2020
CompletedFirst Posted
Study publicly available on registry
April 2, 2020
CompletedStudy Start
First participant enrolled
April 6, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 13, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
May 8, 2020
CompletedResults Posted
Study results publicly available
May 3, 2021
CompletedMay 3, 2021
April 1, 2021
7 days
March 31, 2020
April 6, 2021
April 30, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Email Opened: Control vs. Less-is-better vs. Social Proof vs. Endowment
Whether email was opened (yes / no)
8-10 days post-intervention
Link Clicked: Control vs. Less-is-better vs. Social Proof vs. Endowment
Whether the link / button to start the activation process was clicked (yes / no)
8-10 days post-intervention
Enrollment: Control vs. Less-is-better vs. Social Proof vs. Endowment
Whether the patient enrolled in myGeisinger (yes / no)
8-10 days post-intervention
Secondary Outcomes (9)
Email Opened: Control vs. Less-is-better vs. Social Proof vs. Endowment
32-35 days post-intervention
Link Clicked: Control vs. Less-is-better vs. Social Proof vs. Endowment
32-35 days post-intervention
Enrollment: Control vs. Less-is-better vs. Social Proof vs. Endowment
32-35 days post-intervention
Email Opened: Within Less-is-better (Provider Communication vs. Managing Appointments vs. Medical Information Access)
8-10 days post-intervention
Link Clicked: Within Less-is-better (Provider Communication vs. Managing Appointments vs. Medical Information Access)
8-10 days post-intervention
- +4 more secondary outcomes
Study Arms (6)
Control
A standard marketing message encouraging activation and describing the benefits of myGeisinger
Focused on provider communication
A simple message focused on one benefit of myGeisinger: communicating easily with providers
Focused on scheduling
A simple message focused on one benefit of myGeisinger: scheduling and managing appointments online
Focused on medical information access
A simple message focused on one benefit of myGeisinger: accessing medical information, like test results
Social proof
A message similar to control, but including information about how many other patients are using myGeisinger
Endowment / decision staging
A message similar to control, but framing myGeisinger as something that patients already have, and just need to take one more step to activate. Endowment: Give patients the impression they already have the account, so they value it more. Decision staging: Break down the process into multiple stages - "having" an account and "activating" that account- and giving the impression that they are almost there because the first stage is complete
Interventions
Eligibility Criteria
The population consists of Geisinger patients whose myGeisinger status is "Pending" and who have an email address on file.
You may qualify if:
- Geisinger patients whose myGeisinger status is "Pending", meaning an activation code has been generated for them, but they have not completed activation
You may not qualify if:
- Patients without email addresses on file
- Patients who received emails from this monthly myGeisinger marketing campaign within the last 2 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Geisinger Cliniclead
Study Sites (1)
Geisinger
Danville, Pennsylvania, 17822, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Limitations and Caveats
For this study, we only received data about engagement with the email and enrollment in the patient portal. Demographic information such as age, sex, or gender were not collected. Note that for some patients, enrollment data could not be extracted from Geisinger's electronic health records; these patients were excluded from analyses. Also note that "1 week" and "1 month" outcome data were extracted within a time range that was a few days longer than 7 and 30 days post-intervention, respectively.
Results Point of Contact
- Title
- Amir Goren, PhD
- Organization
- Geisinger Clinic
Study Officials
- PRINCIPAL INVESTIGATOR
Amir Goren, PhD
Geisinger Clinic
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Program Director, Behavioral Insights Team
Study Record Dates
First Submitted
March 31, 2020
First Posted
April 2, 2020
Study Start
April 6, 2020
Primary Completion
April 13, 2020
Study Completion
May 8, 2020
Last Updated
May 3, 2021
Results First Posted
May 3, 2021
Record last verified: 2021-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- ANALYTIC CODE
- Time Frame
- The data will become available after publication of study results in a scientific journal and will be available as long as the Open Science Framework hosts the data.
- Access Criteria
- The data on the Open Science Framework will be open to anyone requesting that information.
Data with no personally identifiable information will be made available to other researchers on the Open Science Framework for transparency. This will include the essential data and code needed to replicate the analysis that yielded reported findings.